Cerubidine Articles

AS1413 achieves 42% remission rate in AML

15 December 2008

Diatos acquires DaunoXome from Gilead for $4.7M

15 May 2006

APP buys Bigmar's European facility and products

2 August 2004

OSI acquires oncology assets from Gilead in $200 million deal

27 November 2001

SuperGen's leukemia drug cleared in USA

22 November 2001

Spain's Zeltia preparing for product launches and partnering deals

2 August 2001

Despite revenue rise, Gilead loss increases

1 May 2001

Gilead Sciences to merge with NeXstar

2 March 1999

Novartis' Exelon Cleared In First Major Market

14 May 1998

Excellent Year For The Biotechnology Industry

16 December 1996

Encouraging Results With NeXstar's DaunoXome

15 July 1996

Xenova Starts Trials Of Second Cancer Drug

17 June 1996

NeXstar's DaunoXome Sees US Launch

13 May 1996

USA Approves NeXstar's DaunoXome For KS

15 April 1996

DaunoXome Launches

1 April 1996

Sandoz MDR Drug Shows Promise In Early Trials

13 November 1995

NeXstar hears FDA news on DaunoXome

16 October 1995

Medi-Physics' Myoview approvable + other approvables

25 September 1995

Vestar Daunoxome patent

21 August 1995

FDA Panel Backs NeXstar's DaunoXome...

19 June 1995

New York stock comment

19 June 1995

NeXstar Gains First Approval For Daunoxome

12 June 1995

NeXstar's DaunoXome Slated For FDA Committee Review In June

24 April 1995

Chiron/ Ben Venue Acquisition

10 April 1995

CPAC Approves Six Drugs In Japan

3 April 1995

DaunoXome Results In Kaposi's Sarcoma

28 November 1994

Anticancer Drugs In Development In Japan

24 October 1994

VESTAR FILES PLA IN UK

11 July 1994

ENZON'S ONCASPAR APPROVED IN USA

14 February 1994

FDA PANEL REJECTS DAUNOXOME NDA

28 June 1993

VESTAR DAUNOXOME EARLY FILING SUPRISE

22 March 1993

Showing 1-31 of 31 articles

Go to beginningPrevious
  • 1
NextGo to end